Tumor DNA and cellular components

Tumor DNA and cellular components represent a broad category of therapeutic targets primarily addressed by traditional cytotoxic chemotherapies [PubMed]. Tumor DNA serves as the primary repository of genetic information, and its integrity is essential for the survival and proliferation of malignant cells [NIH]. Drugs targeting these components often work by inducing irreversible damage, such as DNA cross-linking, alkylation, or intercalation, which triggers programmed cell death or apoptosis [StatPearls]. Beyond DNA, "cellular components" can include structures like microtubules, which are critical for the mitotic spindle during cell division, or the cell membrane [Nature Reviews Cancer]. While effective at killing rapidly dividing cancer cells, these targets are often non-specific, leading to significant side effects in healthy tissues with high turnover rates [Mayo Clinic]. Modern oncology increasingly focuses on specific genetic alterations within the DNA, but the broad targeting of the DNA molecule remains a cornerstone of many treatment regimens [NCI].

Other names

Cancer cell DNATumor cell componentsGenomic DNACellular targets of chemotherapyCytotoxic targetsTumor cell DNA

Drugs targeting these components act through several distinct pathways: alkylating agents and platinum compounds form covalent bonds with DNA bases, leading to cross-links that inhibit replication [StatPearls, PubChem]; anthracyclines intercalate between DNA base pairs and inhibit topoisomerase II [NIH]; antimetabolites substitute for normal nucleotides during DNA synthesis, causing strand breakage [PubMed]; and taxanes or vinca alkaloids bind to tubulin, disrupting the microtubule dynamics necessary for mitotic spindle formation [Nature Reviews Cancer].